glp-1 agonists and health coaching ⚠️ The mistake that's HURTING your clients: Using GLPs without protecting muscle.⁠ ⁠ Here's what happens: → Weight drops ✓ → But so does muscle mass ✗ → Metabolism crashes ✗ Strong Beyond the Shot |

Louis Spread the word in St

The bodys response to GLP-1 is to increase insulin production, slow gastric emptying (so we feel full, and stop eating), and to inhibit glucagon secretion (therefore lowering our blood sugar)

Hormonal fluctuations may also play a role, though this mechanism is not firmly established in GLP-1 users

The April 30, 2026 FDA Proposal: What It Says, What It Doesn't, and What It Means Right Now Every patient researching a compounded GLP-1 program in May 2026 should understand this development before making any enrollment decision

When should I contact an attorney

Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs